The Association between Systemic Inflammation and the Prostate Cancer: based on the National Health and Nutrition Examination Survey and Mendelian Randomization Analysis
Urology Journal,
Vol. 22 No. 03 (2025),
9 September 2025
,
Page 139-146
https://doi.org/10.22037/uj.v21i.8268
Abstract
Purpose: The purpose of this combination research was to examine the relationship between systemic inflammation and the risk of prostate cancer (PCa) through the National Health and Nutrition Examination Survey (NHANES) cross-sectional study and two-sample Mendelian randomization (MR) analysis.
Materials and Methods: We incorporated NHANES data spanning the years 2001 to 2010, with exposure as systemic inflammation, evaluated using systemic immune-inflammation index (SII) and outcome as PCa, and performed multivariate logistic regression and restricted cubic spline (RCS) to test the correlation between SII and PCa. Further, two-sample MR was used to identify causal associations between specific immune cells and PCa.
Results: A total of 7706 participants (age≥40 years) were included in the analysis in the cross-sectional study, including 350 PCa cases, 7356 controls. Higher SII levels were associated with increased odds of PCa (P<.05). The odds ratio (OR) for PCa was 1.51 (95% CI 1.09-2.08) for the highest versus lowest quartile of SII levels in the fully adjusted model. Also, the RCS analysis showed a threshold effect, with SII levels above 8.90 associated with increased odds of PCa. In addition, MR results suggested a causal relationship between CD62L- monocyte, CD62L- HLA DR+ monocyte, CD14+ CD16+ monocyte, CD62L- Dendritic Cell, Monocytic Myeloid-Derived Suppressor Cell, CD28- CD8dim T cell, CD39+ resting CD4 regulatory T cell and PCa (P<.05).
Conclusion: This combination analysis provides evidence for a significant causal relationship between systemic inflammation and PCa risk. These findings highlight systemic inflammation and inflammatory immune responses as potential modifiable risk factors for PCa.
- Systemic inflammation
- Prostate cancer
- NHANES
- Mendelian randomization
- Causality
How to Cite
References
Meng L, Yang Y, Hu X, Zhang R, Li X. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis. Journal of translational medicine. 2023;21:79.
Basiri A, Eshrati B, Zarehoroki A, et al. Incidence, Gleason Score and Ethnicity Pattern of Prostate Cancer in the Multi-ethnicity Country of Iran During 2008-2010. Urology journal. 2020;17:602-6.
Siegel R, Miller K, Wagle N, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023;73:17-48.
Bailey-Whyte M, Minas T, Dorsey T, Smith C, Loffredo C, Ambs S. Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort. Cancers. 2023;15.
Rundle A, Sadasivan S, Chitale D, et al. Racial differences in the systemic inflammatory response to prostate cancer. PloS one. 2021;16:e0252951.
Alessandro R, Matteo S, Veronica M, Michelangelo F, Giovanni B, Francesco M. Microbiota and prostate cancer. Semin Cancer Biol. 2021;86.
Veronica M, Alessandro R, Matteo R, et al. Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers (Basel). 2021;13.
Taha Koray S, Alessandro R, Sercan A, Deniz Can G. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16.
Deniz Can G, Taha Koray S, Enes E, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Mol Biosci. 2022;9.
Matteo R, Matteo S, Veronica M, et al. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021;22.
Pichardo M, Minas T, Pichardo C, et al. Association of Neighborhood Deprivation With Prostate Cancer and Immune Markers in African American and European American Men. JAMA network open. 2023;6:e2251745.
Adhyatma K, Prapiska F, Siregar G, Warli S. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio. Open access Macedonian journal of medical sciences. 2019;7:1628-30.
Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. Cancers. 2020;12.
Luo Z, Wang W, Xiang L, Jin T. Association between the Systemic Immune-Inflammation Index and Prostate Cancer. Nutrition and cancer. 2023;75:1918-25.
Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. Current opinion in urology. 2022;32:594-7.
Guo W, Song Y, Sun Y, et al. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018. Frontiers in endocrinology. 2022;13:1071465.
Liu B, Wang J, Li Y, Li K, Zhang Q. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999-2018. Arthritis research & therapy. 2023;25:34.
Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018. Frontiers in immunology. 2022;13:1058779.
Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and Risk of All-Cause Mortality and Cardiovascular Mortality: A 20-Year Follow-Up Cohort Study of 42,875 US Adults. Journal of clinical medicine. 2023;12.
Tang Y, Peng B, Liu J, Liu Z, Xia Y, Geng B. Systemic immune-inflammation index and bone mineral density in postmenopausal women: A cross-sectional study of the national health and nutrition examination survey (NHANES) 2007-2018. Frontiers in immunology. 2022;13:975400.
Chen X, Kong J, Diao X, et al. Depression and prostate cancer risk: A Mendelian randomization study. Cancer medicine. 2020;9:9160-7.
Li Y, Sundquist K, Zhang N, Wang X, Sundquist J, Memon A. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types. EBioMedicine. 2023;88:104432.
Bouras E, Karhunen V, Gill D, et al. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC medicine. 2022;20:3.
Yuan S, Mason A, Titova O, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study. International journal of cancer. 2023;152:697-704.
Taheri M, Badrlou E, Hussen B, Kashi A, Ghafouri-Fard S, Baniahmad A. Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer. Frontiers in oncology. 2023;13:1123101.
Qin Z, Li H, Wang L, et al. Systemic Immune-Inflammation Index Is Associated With Increased Urinary Albumin Excretion: A Population-Based Study. Frontiers in immunology. 2022;13:863640.
Wang M, Jian Z, Yuan C, Jin X, Li H, Wang K. Coffee Consumption and Prostate Cancer Risk: Results from National Health and Nutrition Examination Survey 1999-2010 and Mendelian Randomization Analyses. Nutrients. 2021;13.
Cao R, Yu X, Xiong M, Li X, Deng F, Lei S. The immune factors have complex causal regulation effects on bone mineral density. Frontiers in immunology. 2022;13:959417.
Orrù V, Steri M, Sidore C, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nature genetics. 2020;52:1036-45.
Birney E. Mendelian Randomization. Cold Spring Harbor perspectives in medicine. 2022;12.
Emdin C, Khera A, Kathiresan S. Mendelian Randomization. JAMA. 2017;318:1925-6.
Sander G, Mohammad Ali M, Michael J. To curb research misreporting, replace significance and confidence by compatibility: A Preventive Medicine Golden Jubilee article. Prev Med. 2022;164.
Mohammad Ali M, Maryam N, Mahyar E. P-value, compatibility, and S-value. Glob Epidemiol. 2023;4.
Weng H, Li H, Zhang Z, et al. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health West Pac. 2023;39:100848.
Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, Inflammation, and Prostate Cancer. Journal of clinical medicine. 2019;8.
Patel H, Patel B. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life sciences. 2017;170:56-63.
Olivas A, Price R. Obesity, Inflammation, and Advanced Prostate Cancer. Nutrition and cancer. 2021;73:2232-48.
Yin Q, Song D, Chen J, Ning G, Wang W, Wang S. The CD14CD16 monocyte subset is expanded and controls Th1 cell development in Graves' disease. Clinical immunology (Orlando, Fla.). 2022;245:109160.
Nakajima Y, Chamoto K, Oura T, Honjo T. Critical role of the CD44CD62L CD8 T cell subset in restoring antitumor immunity in aged mice. Proceedings of the National Academy of Sciences of the United States of America. 2021;118.
Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nature medicine. 2011;17:1290-7.
Wei H, Li Y, Guo Z, et al. Comparison of dynamic changes in the peripheral CD8 T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy. Frontiers in immunology. 2022;13:1060695.
Cassetta L, Fragkogianni S, Sims A, et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. Cancer cell. 2019;35:588-602.e10.
Geissmann F, Manz M, Jung S, Sieweke M, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (New York, N.Y.). 2010;327:656-61.
Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. The Journal of clinical investigation. 2016;126:3279-95.
Pawelec G, Picard E, Bueno V, Verschoor C, Ostrand-Rosenberg S. MDSCs, ageing and inflammageing. Cellular immunology. 2021;362:104297.
Gao F, Xu Q, Tang Z, et al. Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression via S100A9/circMID1/miR-506-3p/MID1. Journal of translational medicine. 2022;20:346.
Koinis F, Xagara A, Chantzara E, Leontopoulou V, Aidarinis C, Kotsakis A. Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives. Cells. 2021;11.
Sharma A, Subudhi S, Blando J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019;25:1233-8.
Alvisi G, Termanini A, Soldani C, et al. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. Journal of hepatology. 2022;77:1359-72.
Fujii S, Shimizu K. Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer. Trends in immunology. 2019;40:984-97.
Wen Y, Zhu Y, Zhang C, et al. Chronic inflammation, cancer development and immunotherapy. Frontiers in pharmacology. 2022;13:1040163.
Porter C, Shrestha E, Peiffer L, Sfanos K. The microbiome in prostate inflammation and prostate cancer. Prostate cancer and prostatic diseases. 2018;21:345-54.
Reuter S, Gupta S, Chaturvedi M, Aggarwal B. Oxidative stress, inflammation, and cancer: how are they linked? Free radical biology & medicine. 2010;49:1603-16.
Li H, Meng Y, He S, et al. Macrophages, Chronic Inflammation, and Insulin Resistance. Cells. 2022;11.
Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine & growth factor reviews. 2018;44:38-50.
Ferro M, Terracciano D, Buonerba C, et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future oncology (London, England). 2017;13:285-93.
- Abstract Viewed: 1810 times
- 8268/pdf Downloaded: 250 times